Nauman Shah leads a global team charged with driving business development strategy and pursuing transformational acquisitions, licensing, and partnership opportunities to advance Johnson & Johnson’s mission to save and improve lives. Working closely with the external biotech innovation ecosystem and financial community, Nauman helps evolve Johnson & Johnson’s strategic portfolio by identifying and sourcing external innovation opportunities to accelerate positive patient impact and create value for the company. A member of the Innovative Medicine Group Operating Committee, Nauman has extensive experience successfully activating engagement, collaboration, and talent development across large, cross-functional teams. Nauman joined Johnson & Johnson in 2003 and has since held various leadership positions in marketing and Enterprise operations. He previously led Johnson & Johnson MedTech’s Strategic Customer team to launch value-based care programs that enhance operational efficiency for healthcare systems. Formerly the Chief of Staff to the former Chairman and CEO, Nauman was directly involved in the company’s strategic planning process and executing enterprise growth initiatives. Notably during his tenure in marketing, he led the launches of multiple new products, including: TOPAMAX, XARELTO, and INVOKANA. Throughout his career, Nauman has championed initiatives that advance new capabilities and enable greater collaboration — all aimed at delivering on Johnson & Johnson’s mission to profoundly improve health for humanity. Prior to joining Johnson & Johnson, Nauman worked at Pfizer/Pharmacia, where he played a significant role in successfully launching three major products in urology, arthritis, and pain. He holds a Bachelor of Arts degree in Biological Basis of Behavior from the University of Pennsylvania and a Master of Business Administration in Finance from Temple University. He graduated from the Wharton School of the University of Pennsylvania after completing the General Management Program.